ArticleKorean journal of ophthalmology : KJO2025
Efficacy and Safety of 7.2 J/cm2 Accelerated Corneal Cross-Linking in Pediatric and Adult Keratoconus: A Comparative Study.
Article in Korean journal of ophthalmology : KJO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Variation in corneal biomechanical properties following continuous cross-linking treatment.Eye and vision (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate and compare the short-term outcomes of an accelerated corneal cross-linking (CXL) protocol with a total energy dose of 7.2 J/cm2 in pediatric and adult keratoconus patients.
methodsThis study included 113 eyes of 82 keratoconus patients who underwent accelerated epithelium-off CXL (12 mW/cm2 for 10 minutes) at a university hospital. Patients were divided into two groups based on age: <18 years (group 1, 48 eyes; mean age, 15.4 ± 1.6 years) and ≥18 years (group 2, 65 eyes; mean age, 23.4 ± 3.4 years). Preoperative and postoperative (6-month) uncorrected visual acuity, best-corrected visual acuity, keratometric indices, central corneal thickness, and endothelial cell density were analyzed and compared between groups.
resultsSignificant improvements in best-corrected visual acuity and reductions in keratometric indices were observed in both groups (p < 0.05). While both groups demonstrated significant visual and structural improvements, group 2 exhibited a greater magnitude of change in most keratometric and refractive parameters. Both groups exhibited significant decreases in central corneal thickness (p < 0.001). Posterior keratometric values showed statistically significant changes in both groups (p < 0.001). Endothelial cell density remained stable, and no severe complications were noted.
conclusionsAccelerated CXL with a total energy dose of 7.2 J/cm2 demonstrated a favorable safety profile and significant efficacy in stabilizing keratoconus in both pediatric and adult patients over a 6-month period. Notably, adult patients exhibited a greater extent of keratometric and refractive improvement, suggesting a potentially age-dependent biomechanical response. These findings support the utility of this protocol as an early intervention strategy, particularly in young adults with progressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.